Hypofractionated IMRT of the Prostate Bed After Radical Prostatectomy: Acute Toxicity in the PRIAMOS-1 Trial

Published:September 10, 2014DOI:


      Hypofractionated radiation therapy as primary treatment for prostate cancer is currently being investigated in large phase 3 trials. However, there are few data on postoperative hypofractionation. The Radiation therapy for the Prostate Bed With or Without the Pelvic Lymph Nodes (PRIAMOS 1) trial was initiated as a prospective phase 2 trial to assess treatment safety and toxicity of a hypofractionated intensity modulated radiation therapy (IMRT) of the prostate bed.

      Methods and Materials

      From February to September 2012, 40 patients with indications for adjuvant or salvage radiation therapy were enrolled. One patient dropped out before treatment. Patients received 54 Gy in 18 fractions to the prostate bed with IMRT and daily image guidance. Gastrointestinal (GI) and genitourinary (GU) toxicities (according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0) were recorded weekly during treatment and 10 weeks after radiation therapy.


      Overall acute toxicity was favorable, with no recorded adverse events grade ≥3. Acute GI toxicity rates were 56.4% (grade 1) and 17.9% (grade 2). Acute GU toxicity was recorded in 35.9% of patients (maximum grade 1). Urinary stress incontinence was not influenced by radiation therapy. The incidence of grade 1 urinary urge incontinence increased from 2.6% before to 23.1% 10 weeks after therapy, but grade 2 urge incontinence remained unchanged.


      Postoperative hypofractionated IMRT of the prostate bed is tolerated well, with no severe acute side effects.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fowler J.F.
        The linear-quadratic formula and progress in fractionated radiotherapy.
        Br J Radiol. 1989; 62: 679-694
        • Fowler J.F.
        • Toma-Dasu I.
        • Dasu A.
        Is the alpha/beta ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?.
        Anticancer Res. 2013; 33: 1009-1011
        • Fowler J.F.
        The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
        Acta Oncol. 2005; 44: 265-276
        • Lee W.R.
        Prostate cancer and the hypofractionation hypothesis.
        J Clin Oncol. 2013; 31: 3849-3851
        • Yeoh E.E.
        • Botten R.J.
        • Butters J.
        • et al.
        Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: Final results of phase III randomized trial.
        Int J Radiat Oncol Biol Phys. 2011; 81: 1271-1278
        • Lukka H.
        • Hayter C.
        • Julian J.A.
        • et al.
        Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
        J Clin Oncol. 2005; 23: 6132-6138
        • Arcangeli G.
        • Saracino B.
        • Gomellini S.
        • et al.
        A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2010; 78: 11-18
        • Arcangeli S.
        • Strigari L.
        • Gomellini S.
        • et al.
        Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2012; 84: 1172-1178
        • Kuban D.A.
        • Nogueras-Gonzalez G.M.
        • Hamblin L.
        Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation.
        Int J Radiat Oncol Biol Phys. 2010; 78: 58-59
        • Krause S.
        • Sterzing F.
        • Neuhof D.
        • et al.
        Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trial.
        BMC Cancer. 2012; 12: 504
        • Thompson I.M.
        • Valicenti R.K.
        • Albertsen P.
        • et al.
        Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline.
        J Urol. 2013; 190: 441-449
        • Emami B.
        • Lyman J.
        • Brown A.
        • et al.
        Tolerance of normal tissue to therapeutic irradiation.
        Int J Radiat Oncol Biol Phys. 1991; 21: 109-122
        • Michalski J.M.
        • Gay H.
        • Jackson A.
        • et al.
        Radiation dose-volume effects in radiation-induced rectal injury.
        Int J Radiat Oncol Biol Phys. 2010; 76: S123-S129
        • D'Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        JAMA. 1998; 280: 969-974
        • Pollack A.
        • Hanlon A.L.
        • Horwitz E.M.
        • et al.
        Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.
        Int J Radiat Oncol Biol Phys. 2006; 64: 518-526
        • Pollack A.
        • Walker G.
        • Horwitz E.M.
        • et al.
        Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.
        J Clin Oncol. 2013; 31: 3860-3868
        • Zaorsky N.G.
        • Ohri N.
        • Showalter T.N.
        • et al.
        Systematic review of hypofractionated radiation therapy for prostate cancer.
        Cancer Treat Rev. 2013; 39: 728-736
        • Cabrera A.R.
        • Lee W.R.
        Hypofractionation for clinically localized prostate cancer.
        Semin Radiat Oncol. 2013; 23: 191-197
        • Wiegel T.
        • Bottke D.
        • Steiner U.
        • et al.
        Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
        J Clin Oncol. 2009; 27: 2924-2930
        • Thompson I.M.
        • Tangen C.M.
        • Paradelo J.
        • et al.
        Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastasis and improves survival: Long-term followup of a randomized clinical trial.
        J Urol. 2009; 181: 956-962
        • Bolla M.
        • van Poppel H.
        • Tombal B.
        • et al.
        Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911).
        Lancet. 2012; 380: 2018-2027
        • Syndikus I.
        • Pickles T.
        • Kostashuk E.
        • et al.
        Postoperative radiotherapy for stage pT3 carcinoma of the prostate: Improved local control.
        J Urol. 1996; 155: 1983-1986
        • Lee L.W.
        • McBain C.A.
        • Swindell R.
        • et al.
        Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy.
        Clin Oncol (R Coll Radiol). 2004; 16: 517-522
        • Wong G.W.
        • Palazzi-Churas K.L.
        • Jarrard D.F.
        • et al.
        Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 2008; 70: 449-455
        • Kruser T.J.
        • Jarrard D.F.
        • Graf A.K.
        • et al.
        Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.
        Cancer. 2011; 117: 2629-2636
        • Massaccesi M.
        • Cilla S.
        • Deodato F.
        • et al.
        Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: Preliminary results of a phase II trial.
        Anticancer Res. 2013; 33: 2785-2789
        • Cozzarini C.
        • Fiorino C.
        • Di Muzio N.
        • et al.
        Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: Planning data and toxicity results of a Phase I-II study.
        Radiother Oncol. 2008; 88: 26-33
        • Bellavita R.
        • Massetti M.
        • Abraha I.
        • et al.
        Conformal postoperative radiotherapy in patients with positive resection margins and/or pT3-4 prostate adenocarcinoma.
        Int J Radiat Oncol Biol Phys. 2012; 84: e299-304
        • Zelefsky M.J.
        • Aschkenasy E.
        • Kelsen S.
        • et al.
        Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy.
        Int J Radiat Oncol Biol Phys. 1997; 39: 327-333
        • Cozzarini C.
        • Montorsi F.
        • Fiorino C.
        • et al.
        Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: A single-institution analysis of 334 high-risk, node-negative patients.
        Int J Radiat Oncol Biol Phys. 2009; 75: 966-974
        • Riou O.
        • Fenoglietto P.
        • Laliberte B.
        • et al.
        Three years of salvage IMRT for prostate cancer: Results of the Montpellier Cancer Center.
        ISRN Urol. 2012; 2012: 391705
        • Nath S.K.
        • Sandhu A.P.
        • Rose B.S.
        • et al.
        Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2010; 78: 435-441
        • Bauman G.
        • Rumble R.B.
        • Chen J.
        • et al.
        Intensity-modulated radiotherapy in the treatment of prostate cancer.
        Clin Oncol (R Coll Radiol). 2012; 24: 461-473
        • Kupelian P.A.
        • Willoughby T.R.
        • Reddy C.A.
        • et al.
        Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2008; 70: 1146-1150
        • De Meerleer G.
        • Fonteyne V.
        • Meersschout S.
        • et al.
        Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy.
        Radiother Oncol. 2008; 89: 205-213
        • Neuhof D.
        • Hentschel T.
        • Bischof M.
        • et al.
        Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
        Int J Radiat Oncol Biol Phys. 2007; 67: 1411-1417


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.